Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Rep. Chris Collins January 2020
Biotech

Former Rep. Chris Collins sentenced to 26 months in prison in biotech insider trading scheme

By Damian Garde and Lev Facher

Biotech

How swallowing a star might keep you from missing a dose of medicine

By Jonathan Saltzman — Boston Globe

JPM 2020 Lombard St
Adam's Take

The truth about JPM: Less is more

By Adam Feuerstein

Alexis Borisy and Melanie Nallicheri
Biotech

‘We have a tragedy of the commons’: How a VC thinks his new company can lower drug prices

By Adam Feuerstein and Matthew Herper

Brain neurons
Biotech

A venture firm warms to funding neuroscience

By Matthew Herper

Regeneron HQ
Biotech

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

By Adam Feuerstein

STAT SPOTLIGHT
Biotech

Startup Spotlight: With a different method for gene therapy, Generation Bio eyes an IPO

By Kate Sheridan

Fatty Liver
Biotech

On the cusp of FDA approval for its NASH drug, Intercept’s CEO talks payers, pruritis, and price

By Adam Feuerstein

Patrick Soon-Shiong
Biotech

After a single patient drives a big stock surge, Patrick Soon-Shiong makes his case to investors

By Rebecca Robbins

JPM 2020 Lombard St
Biotech

At JPM, a debate on Alzheimer’s disease, some family drama in oncology, and a beaten-down biotech

By Adam Feuerstein, Matthew Herper, and Damian Garde

JPM 2020 Lombard St
Adam's Take

All talk, no M&A makes for a down JPM Day

By Adam Feuerstein

AstraZeneca signage
Biotech

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

By Matthew Herper

Biotech

Agios CEO forecasts ‘line of sight’ to more approved drugs and profits

By Adam Feuerstein

Alexis Borisy portrait
Biotech

A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down

By Matthew Herper

Biotech

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

By Adam Feuerstein

DNA strand repair
Biotech

Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer

By Jonathan Saltzman — Boston Globe

Regeneron HQ
Biotech

Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease

By Damian Garde

JPM 20 years illustration
Biotech

The ghosts of JPMs past: How 20 years of deals, scandal, and science have shaped health care

By Matthew Herper, Damian Garde, Rebecca Robbins, and Adam Feuerstein

Dr. Patrick Soon-Shiong, Cancer MoonShot 2016
Biotech

At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find

By Rebecca Robbins

Adam's Take

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

By Adam Feuerstein

Knee replacement
Biotech

Anika Therapeutics acquires two companies for their joint-replacement products

By Jonathan Saltzman — Boston Globe

Shattered blood cell
Biotech

Apellis Pharmaceuticals’ drug candidate outperforms Alexion’s Soliris in a clinical trial comparing the two

By Kate Sheridan

Adam's Take

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

By Adam Feuerstein

Scorecard
Biotech

The biotech scorecard for the first quarter: 14 stock-moving events to watch

By Adam Feuerstein

Jary Larsen
Biotech

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

By Jonathan Saltzman — Boston Globe

2010- 2019 Medicine
Biotech

STAT’s guide to the most important, beneficial drugs approved in the past decade

By Adam Feuerstein and Matthew Herper

Biotech graveyard
Biotech

Crash and burn: The four biggest biopharma failures of 2019

By Kate Sheridan

2019 to Watch Biotech
Biotech

3 trends in biotech to watch in 2020

By Damian Garde

Cambridge: Sarepta
Biotech

Sarepta sells international rights to Duchenne gene therapy to Roche

By Adam Feuerstein

Your daily dose of news in health and medicine

Privacy Policy